Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9Y210
UPID:
TRPC6_HUMAN
Alternative names:
Transient receptor protein 6
Alternative UPACC:
Q9Y210; Q52M59; Q9HCW3; Q9NQA8; Q9NQA9
Background:
Short transient receptor potential channel 6, alternatively known as Transient receptor protein 6, plays a pivotal role in cellular functions by forming a receptor-activated non-selective calcium permeant cation channel. It is activated by diacylglycerol (DAG) in a unique manner, independent of protein kinase C, and is thought to be part of a phosphatidylinositol second messenger system triggered by receptor tyrosine kinases or G-protein coupled receptors.
Therapeutic significance:
The protein's involvement in Focal segmental glomerulosclerosis 2, a renal pathology leading to severe renal insufficiency, highlights its potential as a target for therapeutic intervention. Understanding the role of Short transient receptor potential channel 6 could open doors to novel strategies for treating this debilitating disease.